2023
(394) Effects of Age, Body Mass Index (BMI) and Diabetic Status on Testosterone Levels, Testosterone Dosing and Safety in Hypogonadal Men Treated with an Oral Testosterone Undecanoate (JATENZO)
Honig S, Swerdloff R, Wang C, Rohowsky N, Newmark J, Seo B, Dudley R. (394) Effects of Age, Body Mass Index (BMI) and Diabetic Status on Testosterone Levels, Testosterone Dosing and Safety in Hypogonadal Men Treated with an Oral Testosterone Undecanoate (JATENZO). The Journal Of Sexual Medicine 2023, 20: qdad060.368. DOI: 10.1093/jsxmed/qdad060.368.Peer-Reviewed Original ResearchBody mass indexOral testosterone undecanoateNon-diabetic groupTestosterone replacement therapyDiabetes statusDiabetic statusFinal doseDiabetic groupHypogonadal menTestosterone undecanoateT levelsEugonadal rangeBMI groupsMass indexHigher body mass indexDose-titration trialFinal mean dosesKey efficacy variablesTotal T levelsTotal T valuesHigh BMI groupStandard clinical measuresPlasma T levelsOral TULiver transaminases
2022
Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety.
Honig S, Gittelman M, Kaminetsky J, Wang C, Amory J, Rohowsky N, Dudley R, Woun Seo B, Newmark J, Swerdloff R. Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety. The Journal Of Sexual Medicine 2022, 19: 1750-1758. PMID: 37057401, DOI: 10.1016/j.jsxm.2022.09.002.Peer-Reviewed Original ResearchConceptsTestosterone replacement therapyPsychosexual Daily QuestionnaireLiver function testsOral TUSerum T concentrationsSexual functionT concentrationsTU therapyHypogonadal menFunction testsEffective long-term treatment optionProstate-specific antigen levelHigh-density lipoprotein cholesterolLong-term treatment optionAdult hypogonadal menOral testosterone undecanoateTotal testosterone levelsSystolic blood pressureTotal T concentrationsActive-controlled trialYears of treatmentLong-term safetySignificant changesEugonadal rangeCardiovascular endpoints012 Two-Year Administration Data of an Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men
Swerdloff R, Honig S, Wang C, Gittelman M, Seo B, Rohowsky N, Dudley R. 012 Two-Year Administration Data of an Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men. The Journal Of Sexual Medicine 2022, 19: s128-s128. DOI: 10.1016/j.jsxm.2022.03.548.Peer-Reviewed Original ResearchTestosterone replacement therapyHypogonadal menOral TUEugonadal rangeSystolic BPSafety profileTrial 2T concentrationsDose-titration trialInjection site painMo of therapyDays of therapyIPSS total scoreLong-term efficacyTrial 1Two-year followMean T concentrationsLong-term extensionPreferred administration routeMen ages 18CV endpointsLFT elevationsALT levelsSite painAE reporting3 Two-Year Administration Data of an Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men
Swerdloff R, Honig S, Wang C, Gittelman M, Seo B, Rohowsky N, Dudley R. 3 Two-Year Administration Data of an Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men. The Journal Of Sexual Medicine 2022, 19: s2-s2. DOI: 10.1016/j.jsxm.2022.01.014.Peer-Reviewed Original ResearchTestosterone replacement therapyHypogonadal menOral TUEugonadal rangeSystolic BPSafety profileTrial 2T concentrationsDose-titration trialInjection site painMo of therapyDays of therapyIPSS total scoreLong-term efficacyTrial 1Two-year followMean T concentrationsLong-term extensionPreferred administration routeMen ages 18CV endpointsLFT elevationsALT levelsSite painAE reporting